Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 38 | SFEBES2015 | Next issue

Society for Endocrinology BES 2015

Edinburgh, UK
02 Nov 2015 - 04 Nov 2015

Card image cap
2-4 November 2015, Edinburgh, UK Further information

Clinical Management Workshops

Workshop 1: How do I do it? (Supported by <emphasis role="italic">Clinical Endocrinology</emphasis> and <emphasis role="italic">Endocrinology, Diabetes &amp; Metabolism Case Reports</emphasis>)

ea0038cmw1.1 | Workshop 1: How do I do it? (Supported by <emphasis role="italic">Clinical Endocrinology</emphasis> and <emphasis role="italic">Endocrinology, Diabetes &amp; Metabolism Case Reports</emphasis>) | SFEBES2015

How do I report and interpret a dual-energy X-ray absorptiometry scan?

Peel Nicola

Dual-energy X-ray absorptiometry (DXA) forms an important component of fracture risk assessment. The objective of the report is to enable confident management by the non-expert recipient. A good report summarises the relevant information, provides a clear clinical interpretation and may also provide detailed management recommendations or refer to agreed management protocols. It needs to achieve a balance between over-simplification and inclusion of unnecessary detail.<p cl...

ea0038cmw1.4 | Workshop 1: How do I do it? (Supported by <emphasis role="italic">Clinical Endocrinology</emphasis> and <emphasis role="italic">Endocrinology, Diabetes &amp; Metabolism Case Reports</emphasis>) | SFEBES2015

How do I manage adrenal suppression?

Tomlinson Jeremy

Two to three percent of the UK population are prescribed glucocorticoid (GC) therapy and their adverse effects are associated with significant morbidity and mortality. Suppression of the hypothalamo-pituitary–adrenal (HPA) axis with the potential risk of adrenal crisis is a recognised complication of therapy. There are significant clinical challenges, not only recognition and diagnosis of the condition, but also in terms of management. There is no doubt that the prevalenc...

ea0038cmw1.5 | Workshop 1: How do I do it? (Supported by <emphasis role="italic">Clinical Endocrinology</emphasis> and <emphasis role="italic">Endocrinology, Diabetes &amp; Metabolism Case Reports</emphasis>) | SFEBES2015

How do I prevent thyroid eye disease after radioiodine?

Boelaert Kristien

Thyrotoxicosis is a common disorder affecting up to 3% of the UK population and Graves’ disease is the most common aetiology. Clinically relevant thyroid eye disease is present in 25–50% of patients with Graves’ disease causing significant disfigurement and morbidity in 5–10% of patients. At the onset of ophthalmopathy, 80–90% of patients have hyperthyroidism, with the rest having euthyroidism or hypothyroidism. Risk factors for development of eye comp...

ea0038cmw1.6 | Workshop 1: How do I do it? (Supported by <emphasis role="italic">Clinical Endocrinology</emphasis> and <emphasis role="italic">Endocrinology, Diabetes &amp; Metabolism Case Reports</emphasis>) | SFEBES2015

How do I manage suspected non compliance for thyroxine replacement?

Gilbert Jacqueline

Optimal treatment of hypothyroidism is usually anticipated to require a daily dose of 1.6–1.8 μg/kg (body weight)/day of levothyroxine (L-T4) in order to restore the TSH within the normal range. Patients who require significantly larger doses of L-T4 than anticipated, e.g., >2 μg/kg body weight of L-T4/day with a persistently elevated TSH warrant further investigation. Biological c...